The study aims to investigate the olfactory TDI score (Threshold, Discrimination, Identification) using the Sniffin' sticks test for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) on dupilumab. Twenty-seven adult patients will be followed up during the treatment with dupilumab on three visits to the Otolaryngology Clinic (Baseline, 3 months and 6 months).
The primary endpoint will be the TDI score. Nasal polyp score, Quality of Olfactory Disorders - negative symptoms (QOD-NS symptom scores), SNOT-22 will be secondary endpoints.
Patients older than 18 years old
Chronic rhinosinusitis with Nasal Polyps
Olfactory loss
Clinical indication for treatment with Dupilumab
Sinonasal malignancies
Trauma
Idiopathic olfactory loss
Use of cocaine
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Lead sponsor
Mount Sinai Hospital, Canada
Collaborator